Lymphangioleiomyomatosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 03 Aug 2026 10:28:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.1.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lymphangioleiomyomatosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Loratadine and Rapamycin for Patients with Lymphangioleiomyomatosis (LAM) https://clinicaltrials.eu/trial/study-on-the-effects-of-loratadine-and-rapamycin-for-patients-with-lymphangioleiomyomatosis-lam/ Mon, 03 Aug 2026 10:28:37 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-loratadine-and-rapamycin-for-patients-with-lymphangioleiomyomatosis-lam/ This clinical trial is focused on studying the effects of a treatment for a rare lung disease called lymphangioleiomyomatosis (LAM). LAM is a condition that affects the lungs and can lead to breathing difficulties. The treatment being tested involves a combination of two medications: loratadine and rapamycin. Loratadine is commonly used to treat allergies, while rapamycin is a medication that helps to prevent the growth of certain cells.

The purpose of this study is to evaluate the safety of using loratadine together with rapamycin over a period of 48 weeks. Participants in the study will be randomly assigned to receive either the combination of loratadine and rapamycin or rapamycin alone. The study will monitor the occurrence of any side effects, such as nausea, diarrhea, abdominal pain, vomiting, headache, and changes in liver function, to understand how the combination treatment compares to using rapamycin by itself.

Throughout the study, researchers will also observe the participants’ overall health, including their lung function and the number of hospital visits they may need. The study aims to determine if the combination treatment can help maintain clinical stability and reduce the need for hospitalizations. The trial will provide valuable information on whether adding loratadine to the treatment plan for LAM patients is safe and beneficial.

]]>